Candida Glabrata

If a yeast infection keeps coming back, or your usual over-the-counter cream and a single fluconazole pill stopped working, the reason often hides in the species. Most vaginal yeast infections are caused by Candida albicans, but a meaningful minority are caused by Candida glabrata (also known as Nakaseomyces glabratus), and this species behaves very differently in your body and in response to treatment.

Knowing whether C. glabrata is present on your vaginal swab changes the playbook. It tells you whether your symptoms are likely to respond to standard azole antifungals or whether your provider should reach for boric acid, flucytosine, or another non-azole approach from the start.

Why Species Identification Matters

Vaginal swabs are the standard way to detect C. glabrata, usually through culture on Sabouraud or chromogenic agar or, increasingly, through molecular nucleic-acid panels that distinguish C. glabrata from C. albicans on the same sample. Identifying the species, not just confirming yeast, is the part that matters for treatment.

C. glabrata is consistently more resistant to fluconazole, the most commonly prescribed oral yeast medication, than C. albicans is. In a two-year study at a Greek center, fluconazole resistance was specifically high in N. glabratus, with cross-resistance to other azoles also noted. In Namibia, all non-albicans species recovered from women with vaginal discharge syndrome were fluconazole resistant. Studies from Ghana, Yemen, and other regions show similar patterns of azole resistance among non-albicans species including C. glabrata. Reaching for the standard yeast pill without species confirmation can leave a C. glabrata infection unresolved for weeks or months.

How Common Is C. glabrata on a Vaginal Swab

How often C. glabrata turns up depends on the population. Across diverse regions, it accounts for a meaningful share of vaginal Candida isolates, typically 5 to 18 percent in most cohorts. In most populations worldwide, including most pregnant cohorts, C. albicans remains dominant (typically 60 to 80 percent of isolates), but in a few specific populations, including one study of pregnant women in Ghana, C. glabrata was reported as the most common species. That finding is an outlier rather than the global norm.

Sources: Vermitsky et al., Maraki et al., Waikhom et al., Ghaddar et al., Anh et al., Dunaiski et al.

What this means for you: if you have recurrent symptoms, pregnancy, diabetes, or recent antibiotic exposure, the probability that your yeast is C. glabrata rather than C. albicans is not negligible. A species-level result changes how aggressively your provider should treat and what medication should be used first.

Recurrent and Treatment-Resistant Infections

C. glabrata is overrepresented in recurrent vulvovaginal candidiasis. In the Greek single-center study, C. glabrata made up roughly a tenth of acute episodes but a much larger share of recurrent cases. Many of these recurrent infections persist precisely because the first-line antifungal is one the yeast can shrug off.

For women already in this loop, swab-based species identification is the diagnostic step that often breaks the cycle. Topical boric acid 600 mg daily for 14 days (the duration recommended by IDSA guidelines and ACOG; the original retrospective series used 2 to 3 weeks and did not find an advantage to extending beyond 14 days) achieved clinical and mycologic success in about 64 to 71 percent of cases in a retrospective series of 141 women with C. glabrata vaginitis. Flucytosine cream nightly for 14 days, used after boric acid or azole failure, succeeded in about 90 percent of those cases (27 of 30 women). These are real options, but only if you know what species you are treating.

Pregnancy and Maternal-Neonatal Concerns

In pregnancy, vulvovaginal candidiasis is common, and in some regions C. glabrata is reported in higher shares. Maternal Candida colonization can be transmitted vertically to a newborn, with notable transmission rates reported in pregnant women in northeast Ethiopia. Untreated symptomatic infection can also be associated with adverse pregnancy outcomes. A systematic review and meta-analysis found that asymptomatic vaginal Candida colonization was not associated with preterm birth or other adverse pregnancy outcomes, although the evidence is not uniform: other studies have linked recurrent asymptomatic colonization to preterm birth, and a separate meta-analysis of treatment trials suggested that treating asymptomatic candidiasis may reduce preterm birth in a post hoc subgroup. The overall picture is mixed.

For pregnant women with symptoms, a species result matters because azole choice in pregnancy is already restricted, and a C. glabrata diagnosis may push treatment toward topical agents proven to work against this species rather than oral fluconazole.

Colonization Versus Infection

A positive swab does not automatically mean infection. C. glabrata can live as part of the vaginal mycobiome (the community of yeasts and fungi in the vagina) at low levels without causing symptoms. In a study of asymptomatic women, colonization without symptoms was frequent. The clinical signal comes from the combination of yeast detection and symptoms like itching, burning, abnormal discharge, or painful intercourse.

This is one of the trickier features of the test. A positive C. glabrata swab in someone with no symptoms is generally observed rather than treated. The same finding in someone with stubborn symptoms is a clear treatment trigger. Reading the result without the symptom context can lead to overtreatment of healthy colonization or undertreatment of real disease.

Why a Single Reading Is Not Enough

Yeast colonization on the vaginal swab is not static. It rises and falls with hormonal cycles, antibiotic exposure, sexual activity, hygiene practices, and the broader balance of bacteria in the vaginal microbiome. A single negative swab during a quiet phase does not rule out a future C. glabrata infection, and a single positive swab without symptoms does not commit you to a course of antifungals.

If you have a history of recurrent yeast infections, retesting during a flare gives the most clinically useful read. If you have started treatment for confirmed C. glabrata, a follow-up swab a few weeks after finishing therapy confirms whether the yeast has actually cleared. For women on suppressive regimens or trying to break a recurrent cycle, repeat swabs every few months during ongoing symptoms, and at the end of a defined treatment course, are reasonable. The point is the trajectory, not any one snapshot.

When Results Can Be Misleading

A vaginal swab can capture different parts of the picture depending on collection and timing. A few situations can distort results:

• Recent antifungal use: a swab taken within days of finishing a course of fluconazole, clotrimazole, or boric acid may temporarily turn negative even if the underlying problem has not resolved. Waiting two to four weeks after treatment ends gives a more honest read.
• Recent antibiotics: broad-spectrum antibiotics shift the vaginal microbiome and can cause yeast that was previously below detection to bloom into a positive swab, even without infection.
• Sampling site: high vaginal swabs collected by a clinician and self-collected swabs both perform well in molecular panels, but inadequate sampling, including collecting from the vulva rather than inside the vaginal canal, can miss organisms.
• Test type: older biochemical identification methods sometimes misidentify C. glabrata as another non-albicans species. Modern molecular and MALDI-TOF (a mass-based fungal ID method) techniques are more accurate.

Decision Pathway for a Positive Result

If your swab is positive for C. glabrata and you have symptoms, the most useful next steps focus on treatment selection and confirmation:

• Pair with full vaginitis panel results: bacterial vaginosis and Trichomonas can coexist with C. glabrata and explain symptoms that persist after yeast treatment. Most molecular panels test all three on the same swab.
• Talk to a clinician about non-azole therapy: topical boric acid or flucytosine has stronger evidence than oral fluconazole for C. glabrata. A gynecologist familiar with recurrent vaginitis is the right specialist if standard treatments have failed.
• Consider underlying drivers: poorly controlled diabetes, immunosuppressive medications, or repeated antibiotic courses raise the odds of recurrent C. glabrata. Addressing these is part of the long-term plan.
• Plan a follow-up swab: a confirmatory test two to four weeks after finishing therapy verifies clearance, particularly important if you have a history of recurrence.

If your swab is positive but you have no symptoms, treatment is generally not warranted. A repeat swab during any future symptom flare is the practical next step.